Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680467 | 0.81 | SCN9A (0.72) | SCN9ASCN5A | |
| SCHEMBL364317 | 0.81 | CES2 (0.53) | SCN9ASCN5A | |
| SCHEMBL10777486 | 0.80 | SCN9A (0.52) | SCN9ASCN5AFLT1FLT4KDR | |
| SCHEMBL16239773 | 0.80 | SCN9A (0.60) | SCN9ASCN5A | |
| SCHEMBL25213585 | 0.80 | CA1 (0.54) | KDM4EMAPK1CLK1 | |
| SCHEMBL30001821 | 0.80 | CYP1A2 (0.49) | KDM4ECLK1 | |
| SCHEMBL15536609 | 0.80 | SCN9A (0.50) | SCN9ASCN5AFLT1FLT4KDR | |
| SCHEMBL15537021 | 0.80 | SCN9A (0.60) | SCN9ASCN5AFLT1FLT4KDR | |
| SCHEMBL22403229 | 0.78 | SCN9A (0.49) | SCN9ASCN5A | |
| SCHEMBL16239610 | 0.78 | SCN9A (0.74) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015051043-A1 | BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2015-04-09 | — | — | WO | disclosed |